ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/medical-oncology/lower-gastrointestinal
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Gastrointestinal (Lower)
60
trial(s) found.
NCT07341737
Advanced
Phase 1 / Phase 2
Not yet recruiting
A Phase 1/2, Multicentre, Open-Label, Dose Escalation and Expansion Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of SL-28 in Patients With Advanced Solid Tumours (
SL-28-FIH
)
allogeneic cell therapy,unspecified mechanism
Bladder cancer
Breast cancer
Cancer
Colorectal cancer
Endometrial cancer
Gastric cancer
Hepatocellular carcinoma
Kidney cancer
Lung adenocarcinoma
Lung cancer
Melanoma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Skin cancer
WA
6009 - Nedlands - Hollywood Private Hospital
NCT07284849
Advanced
Phase 3
Recruiting
A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer (
INCA033890-303
)
anti-VEGF monoclonal antibody
Colorectal cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2500 - Wollongong - Wollongong Hospital
2640 - Albury - Albury Wodonga Regional Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT07272642
Radonc
Phase 1
Not yet recruiting
A Phase 1, Multicenter Study of the Safety and Imaging of NTH-2403, a Lutetium-177 Radiolabeled Monoclonal Antibody Targeting the LRRC15 Epitope, in Participants With Locally Advanced or Metastatic Solid Tumors (
DUNP19
)
Colorectal cancer
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Triple-negative breast cancer
WA
6009 - Nedlands - Hollywood Private Hospital
NCT07262619
Advanced
Phase 1 / Phase 2
Recruiting
A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors, Including Checkpoint Inhibitor Naïve Participants With Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors (
EIK1005-002
)
WRN inhibitor
anti-PD-1 monoclonal antibody
Cancer
Endometrial cancer
Gastric cancer
Microsatellite instability high solid tumour
Mismatch repair deficient colorectal cancer
Solid tumour
dMMR solid cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - GenesisCare North Shore Private Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre
3199 - Frankston - PASO Medical
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
NZ
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT07244705
Advanced
Phase 1 / Phase 2
Recruiting
An Open-label, Multicenter, Phase 1/2 Study Exploring the Safety and Efficacy of ABT-301 in Combination With Tislelizumab and Bevacizumab in Participants With Proficient Mismatch Repair (pMMR)/Non-Microsatellite Instability-High (Non-MSI-H) Locally Advanced or Metastatic Colorectal Cancer (mCRC) (
ABT-301-103
)
HDAC inhibitor
anti-PD-1 monoclonal antibody
anti-VEGF monoclonal antibody
Colorectal cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4120 - Greenslopes - Greenslopes Private Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6009 - Nedlands - Linear Clinical Research
NCT07235293
Advanced
Phase 2
Recruiting
A Randomized, Open-label, Phase 2b Study to Compare the Efficacy of DSP107 in Combination With Atezolizumab Versus Fruquintinib in Patients With Advanced Microsatellite Stable Colorectal Cancer (
DSP107-003
)
VEGFR1/2/3 inhibitor
anti-PD-L1 monoclonal antibody
bifunctional CD47/4-1BB fusion protein
Colorectal cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3011 - Footscray - Footscray Hospital
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT07222800
Advanced
Phase 3
Recruiting
AN INTERVENTIONAL, PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER (
C6461003
)
anti-VEGF monoclonal antibody
Cancer
Colorectal cancer
Gastrointestinal cancer
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
TAS
7000 - Hobart - ICON Cancer Care Hobart
NCT07221357
Advanced
Phase 2 / Phase 3
Recruiting
ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer (
CA266-0003
)
anti-VEGF monoclonal antibody
bispecific PD-L1/VEGFA antibody
Colorectal cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3066 - Epping - Northern Hospital
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
3630 - Shepparton - Goulburn Valley Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4575 - Birtinya - Sunshine Coast University Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT07197580
Radonc
Phase 3
Not yet recruiting
A Phase 3, Randomized, Multi-Center, Open-Label Study to Compare 177Lu-TLX250 (Lutetium (177Lu) Girentuximab Tetraxetan) With the Investigator's Choice of a Single Agent Therapy in Participants With Carbonic Anhydrase 9 (CAIX) Expressing, Advanced Relapsed or Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) (
LUTEON
)
177Lu-anti-CA9-radioconjugate
Clear cell renal cell carcinoma
Colorectal cancer
Kidney cancer
VIC
3051 - North Melbourne - Melbourne Theranostic Innovation Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT07070232
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/II, Open-label, Adaptive Two-part Trial to Evaluate the Safety, Efficacy, Optimal Dose and Pharmacokinetics of BNT326 as Monotherapy and in Combination With Cancer Immunotherapies in Participants With Advanced Solid Tumors (
BNT326-01
)
Itraconazole
Pumitamig
SMO inhibitor
bispecific PD-L1/VEGFA antibody
cancer therapy
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,SMO-targeting
cancer therapy,VEGFA-targeting
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,VEGFA-targeting
Breast cancer
Cervical cancer
Colorectal adenocarcinoma
Gastroesophageal junction adenocarcinoma
Melanoma
Mucosal melanoma
Non-small cell lung cancer
Solid tumour
Uveal melanoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4215 - Southport - Tasman Oncology
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NCT06997497
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 Versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012) (
1084-012
)
KRAS G12C inhibitor
anti-EGFR monoclonal antibody
anti-VEGF monoclonal antibody
Colon adenocarcinoma
Rectal adenocarcinoma
VIC
3168 - Clayton - Monash Medical Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
NCT06974110
Advanced
Phase 1
Recruiting
A Phase 1 Study of MOMA-341 as Monotherapy or Combination Therapy in Participants With Advanced or Metastatic Solid Tumors (
MOMA-341-001
)
WRN inhibitor
Cancer
Colorectal cancer
Endometrial cancer
Gastric cancer
Solid tumour
NSW
2031 - Randwick - Prince of Wales Hospital
2031 - Randwick - Scientia Clinical Research Ltd
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06910657
Advanced
Phase 1
Recruiting
A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors (
VM-002-101
)
oncolytic virus,undisclosed mechanism
Bladder cancer
Breast cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Gastric cancer
Head and neck cancer
Hepatocellular carcinoma
Lung cancer
Melanoma
Oesophageal cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Sarcoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
NCT06820463
Advanced
Phase 2
Recruiting
A Phase 2, Open-Label, Randomized, Master Protocol Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations With Telisotuzumab Adizutecan in Subjects With Metastatic Colorectal Cancer (
AndroMETa-CRC
)
anti-cMET antibody-drug conjugate
Colorectal cancer
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6009 - Nedlands - One Clinical Research
NCT06792695
Advanced
Phase 2
Recruiting
A Phase II, Open-label, Multicenter, Master Protocol to Evaluate the Safety and Efficacy of Novel Study Interventions and Combinations in Participants With Colorectal Cancer (
CANTOR
)
Bevacizumab
Fluorouracil
Irinotecan
Leucovorin
Volrustomig
anti-VEGF monoclonal antibody
antimetabolite
bispecific PD-L1/CTLA4 antibody
cancer therapy
cancer therapy,CTLA4-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,VEGF-targeting
cytotoxic chemotherapy
fluoropyrimidine
immune checkpoint blockade
immune checkpoint blockade,CTLA4-targeting
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,CTLA4-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,VEGF-targeting
therapeutic modality,bispecific antibody
topoisomerase inhibitor
Colorectal cancer
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT06789172
Advanced
Phase 1
Recruiting
A Phase 1, Open-label, Multicenter, Dose-escalation and Cohort Expansion Study of OKN4395, a Triple Antagonist of EP2, EP4, and DP1 Prostanoid Receptors, as Monotherapy and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors (
INVOKE
)
anti-PD-1 monoclonal antibody
prostaglandin EP2/EP4/DP1 receptor inhibitor
Colorectal cancer
Dedifferentiated liposarcoma
Fibrosarcoma
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Pancreatic adenocarcinoma
Sarcoma
Solid tumour
Solitary fibrous tumour
Undifferentiated pleomorphic sarcoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
WA
6009 - Nedlands - Linear Clinical Research
NCT06751329
Advanced
Phase 1
Recruiting
A Phase I, Multicentre, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM002 in Patients With Advanced Solid Tumors (
DM002001
)
bispecific-ERBB3/MUC1 antibody-drug conjugate
Colorectal cancer
Endometrial cancer
Ovarian cancer
Prostate cancer
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2500 - Wollongong - Cancer Care Wollongong
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT06750094
Advanced
Phase 3
Recruiting
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (
OrigAMI-3
)
anti-EGFR monoclonal antibody
anti-VEGF monoclonal antibody
bispecific cMET/EGFR antibody
Colorectal adenocarcinoma
NSW
2139 - Concord - Concord Repatriation General Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Warringal Private Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT06692959
Curative
Phase 2
Not yet recruiting
A Phase II Trial of Neoadjuvant PD-1 Vaccine PD1-Vaxx in Operable MSI High Colorectal Cancer (
Neo-POLEM
)
B cell immunotherapy
IMU-201
Colorectal cancer
NCT06625775
Advanced
Phase 1
Recruiting
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-10203 in Subjects With Advanced Solid Tumors (The BREAKER-101 Study) (
TBBO10203-101
)
PI3K alpha-RAS breaker
Breast cancer
Colorectal cancer
HER2-negative breast cancer
HER2-positive breast cancer
Non-small cell lung cancer
RAS-mutant colorectal cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT06617169
Radonc
Phase 1
Recruiting
Open Label, Phase 1a, Dose-Escalation Study Evaluating the Safety of Fractionated MNPR-101-PCTA-177Lu Dosing in the Treatment of Solid Tumor Cancers (
MNPR101-Lu-1-01
)
177Lu-anti-uPAR radioconjugate
Bladder cancer
Colorectal cancer
Gastric cancer
Lung cancer
Ovarian cancer
Pancreatic cancer
Solid tumour
Triple-negative breast cancer
Urothelial carcinoma
VIC
3051 - North Melbourne - Melbourne Theranostic Innovation Centre
NCT06585488
Advanced
Phase 1
Recruiting
A Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-53038, a Pan-KRAS Inhibitor, as Monotherapy or in Combinations in Patients With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplifications (
BGB-53038-101
)
pan-KRAS inhibitor
Cancer
Colorectal cancer
Gastric cancer
Non-squamous non-small-cell lung cancer
Oesophageal adenocarcinoma
Pancreatic adenocarcinoma
Solid tumour
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06428409
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers (
9999-02A
)
anti-Trop2 antibody-drug conjugate
Biliary tract cancer
Colorectal cancer
Pancreatic adenocarcinoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NCT06400472
Advanced
Phase 1
Recruiting
A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors
anti-FR-alpha antibody-drug conjugate
Cervical cancer
Colorectal cancer
Endometrial cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic cancer
Triple-negative breast cancer
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT06343402
Advanced
Phase 1
Recruiting
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects With Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study (
TBBO8520-101
)
KRAS G12C inhibitor
Colorectal adenocarcinoma
Non-small cell lung cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT06330064
Advanced
Phase 2
Recruiting
A Phase 1B/2 Pan-Tumor, Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02) (
DS7300-203
)
anti-B7H3 antibody-drug conjugate
Breast cancer
Cervical cancer
Colorectal adenocarcinoma
Cutaneous melanoma
Endometrial cancer
Gastrooesophageal adenicarcoma
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Ovarian cancer
Pancreatic adenocarcinoma
Urothelial carcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - GenesisCare North Shore Private Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06252649
Advanced
Phase 3
Recruiting
Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301) (
CodeBreaK-301
)
KRAS G12C/NRAS G12C/HRAS G12C inhibitor
KRAS G12C inhibitor
anti-EGFR monoclonal antibody
anti-VEGF monoclonal antibody
Colorectal cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4350 - Toowoomba - Toowoomba Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5042 - Bedford Park - Flinders Medical Centre
NCT06244771
Advanced
Phase 1 / Phase 2
Recruiting
An Open-Label, Phase 1/2 Dose Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants With KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors (
PROSPER
)
KRAS G12C inhibitor
Colorectal cancer
Non-small cell lung cancer
Pancreatic cancer
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4215 - Southport - Tasman Oncology
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6009 - Nedlands - Linear Clinical Research
NA
NA
NCT06242470
Advanced
Phase 1
Recruiting
A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors (
CP-MGC026-01
)
anti-B7H3 antibody-drug conjugate
Bladder cancer
Breast cancer
Cancer
Castrate-resistant prostate cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Endometrial cancer
Gastric cancer
Gastroesophageal cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Melanoma
Non-small cell lung cancer
Ovarian cancer
Pancreatic cancer
Platinum resistant ovarian cancer
Sarcoma
Small-cell lung cancer
Solid tumour
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT06050707
Radonc
Phase 2
Recruiting
MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach (
MAESTRO
)
radiotherapy
Anal squamous cell carcinoma
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT05855200
Curative
Phase 3
Recruiting
A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy Versus Standard of Care in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
anti-PD-1 monoclonal antibody
Colon adenocarcinoma
Colorectal adenocarcinoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT05759728
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2a, Multicenter, Open-Label, Dose Escalation and Expansion Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Adult Subjects With Metastatic Colorectal Cancer (
CNA3103-001
)
autologous CAR-T-cell therapy,LGR5-targeting
Colorectal adenocarcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT05706129
Radonc
Phase 1 / Phase 2
Recruiting
A Multicenter, Open-Label, Non-Randomized Phase 1/2 Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Patients With Unresectable Locally Advanced or Metastatic Solid Tumors (
ITM-9.4.1.1.01CT
)
radionuclide,CAIX-targeting
Bladder cancer
Clear cell renal cell carcinoma
Colorectal cancer
Head and neck cancer
Pancreatic adenocarcinoma
Squamous non-small-cell lung cancer
Triple-negative breast cancer
Urothelial carcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT05694936
Advanced
Phase 2
Recruiting
A Phase II Trial to Determine the Efficacy of Combining the HDAC Inhibitor Sodium Valproate With EGFR Monoclonal Antibody (Panitumumab or Cetuximab) Maintenance in the First-line Treatment of Patients With RAS Wild Type Metastatic Colorectal Cancer (
VADER
Study).
HDAC inhibitor
anti-EGFR monoclonal antibody
Colorectal cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3199 - Frankston - Peninsula Health Frankston Hospital
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5042 - Bedford Park - Flinders Medical Centre
NCT05462236
Advanced
Phase 2
Recruiting
A Phase II Open Label, Dose-finding run-in and Cohort Expansion Study to Evaluate the Safety, Tolerability and Effectiveness of Tinodasertib in Combination With Pembrolizumab or Irinotecan in Metastatic Colorectal Cancer (
AUM001-2001-MK3475-D65
)
MNK1/2 inhibitor
anti-PD-1 monoclonal antibody
topoisomerase inhibitor
Colorectal cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2500 - Wollongong - Wollongong Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
QLD
4217 - Benowa - Pindara Private Hospital
NCT05411133
Advanced
Phase 1
Recruiting
A Phase 1, First-in-human Study of Cabotamig (ARB202), Bispecific Antibody to CDH17 and CD3 in Advanced Gastrointestinal Malignancies (
A001
)
bispecific T-cell engager,CDH17-targeting
Cholangiocarcinoma
Colorectal adenocarcinoma
Gastric cancer
Gastro-entero-pancreatic neuroendocrine tumour
Gastrointestinal cancer
Hepatocellular carcinoma
Oesophageal adenocarcinoma
Pancreatic cancer
NSW
2217 - Kogarah - St George Private Hospital
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT05253651
Advanced
Phase 3
Recruiting
An Open-label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzumab and mFOLFOX6 Versus mFOLFOX6 Given With or Without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects With HER2+ Metastatic Colorectal Cancer (
MOUNTAINEER-03
)
ERBB2 inhibitor,third generation
anti-EGFR monoclonal antibody
anti-ERBB2 monoclonal antibody
anti-VEGF monoclonal antibody
Colorectal cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT05176483
Advanced
Phase 1
Recruiting
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors (
STELLAR-002
)
MET/VEGFR2/AXL/MER inhibitor
Castrate-resistant prostate cancer
Clear cell renal cell carcinoma
Colorectal cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Non-clear cell renal cell carcinoma
Non-small cell lung cancer
Solid tumour
Urothelial carcinoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2109 - North Ryde - Macquarie University Hospital
2640 - Albury - Border Medical Oncology Research Unit
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4575 - Birtinya - Sunshine Coast University Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NCT05086692
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors (
ABILITY-1
)
IL-2 superkine
Acral lentiginous melanoma
Bladder cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Cutaneous basal cell carcinoma
Cutaneous melanoma
Cutaneous squamous cell carcinoma
Endometrial cancer
Endometrial carcinoma
Epithelial Ovarian Cancer
Fallopian tube cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
Head and neck squamous cell carcinoma
Melanoma
Merkel cell carcinoma
Mucosal melanoma
Non-melanoma skin cancer
Non-squamous non-small-cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic adenocarcinoma
Pleural mesothelioma
Primary peritoneal serous carcinoma
Skin cancer
Solid tumour
Squamous non-small-cell lung cancer
Triple-negative breast cancer
dMMR solid cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
QLD
4120 - Greenslopes - Greenslopes Private Hospital
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
NCT05067283
Advanced
Phase 1
Recruiting
A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Participants With KRAS G12C Mutant Advanced Solid Tumors (
KANDLELIT-001
)
KRAS G12C inhibitor
Colorectal cancer
NOT Non-small cell lung cancer
Non-small cell lung cancer
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3168 - Clayton - Monash Medical Centre
NZ
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT04929223
Advanced
Phase 1
Recruiting
A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) (
WO42758
)
Atezolizumab
Bevacizumab
CDK7 inhibitor
Cetuximab
Divarasib
Inavolisib
KRAS G12C inhibitor
KRAS inhibitor
PI3K alpha inhibitor
SY-5609
Tiragolumab
anti-EGFR monoclonal antibody
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
anti-VEGF monoclonal antibody
cancer therapy
cancer therapy,CDK7-targeting
cancer therapy,EGFR-targeting
cancer therapy,KRAS-targeting
cancer therapy,KRAS G12C-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,TIGIT-targeting
cancer therapy,VEGF-targeting
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immune checkpoint blockade,TIGIT-targeting
immuno-oncology therapy,EGFR-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,TIGIT-targeting
immuno-oncology therapy,VEGF-targeting
Colorectal adenocarcinoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT04895709
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors (
CA052-002
)
anti-CCR8 monoclonal antibody
anti-PD-1 monoclonal antibody
taxane
Cervical cancer
Clear cell renal cell carcinoma
Gastroesophageal junction adenocarcinoma
Head and neck squamous cell carcinoma
Melanoma
Microsatellite stable colorectal cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic adenocarcinoma
Triple-negative breast cancer
Urothelial carcinoma
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2170 - Liverpool - Liverpool Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - One Clinical Research
NCT04585750
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (
PMV-586-101
)
mutant p53 reactivator,Y220C-selective
Bladder cancer
Breast cancer
Colorectal cancer
Endometrial cancer
HER2-negative breast cancer
HER2-positive breast cancer
Head and neck cancer
Lung cancer
NOT Breast cancer
Non-small cell lung cancer
Ovarian cancer
Prostate cancer
Small-cell lung cancer
Triple-negative breast cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - One Clinical Research
NCT04429542
Advanced
Phase 1
Recruiting
First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFβ Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-Driven Advanced Solid Tumors (
BCA101X1101
)
bifunctional EGFR/TGF-beta fusion protein
Anal squamous cell carcinoma
Carcinoma
Colorectal cancer
Cutaneous squamous cell carcinoma
Epithelial Ovarian Cancer
Head and neck cancer
Head and neck squamous cell carcinoma
Pancreatic cancer
Squamous cell carcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT03947385
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions (
IDE196-001
)
PKC inhibitor
Colorectal cancer
Cutaneous melanoma
Solid tumour
Uveal melanoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT03175224
Advanced
Phase 2
Recruiting
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (
SPARTA
)
MET inhibitor,type 1
Cancer
Central nervous system cancer
Colon adenocarcinoma
Gastric cancer
Gastroesophageal junction adenocarcinoma
Glioblastoma
Kidney cancer
Lung cancer
MET:alteration
MET:fusion
Non-small cell lung cancer
Pancreatic cancer
Solid tumour
Thyroid cancer
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
ACTRN12625001151426
Radonc
Not Applicable
Not yet recruiting
Feasibility of delivering High Dose Palliative Radiotherapy in patients with Metastatic malignancy (
HD-PRiMe
)
radiotherapy
Bladder cancer
Cancer
Colorectal cancer
Cutaneous squamous cell carcinoma
Head and neck cancer
Non-small cell lung cancer
Oesophageal cancer
Pancreatic cancer
Skin cancer
Triple-negative breast cancer
QLD
4575 - Birtinya - Sunshine Coast University Hospital
ACTRN12625001005448
Radonc
Not Applicable
Not yet recruiting
Functional imaging-guided radiotherapy short course dose escalation in rectal adenocarcinoma: a feasibility study (
FIGR-Short
)
radiotherapy
Rectal adenocarcinoma
QLD
4575 - Birtinya - Sunshine Coast University Hospital
ACTRN12625000583448
Radonc
Phase 2
Recruiting
Total Neoadjuvant Therapy for Organ Preservation in Early-Stage Low Rectal Cancer: The EARLY-TNT Trial (
EARLY-TNT-Trial
)
Capecitabine
Fluorouracil
Leucovorin
Oxaliplatin
Radiotherapy
antimetabolite
cancer therapy
cytotoxic chemotherapy
fluoropyrimidine
platinum-based antineoplastic agent
Rectal adenocarcinoma
ACTRN12625000203459
Advanced
Phase 1 / Phase 2
Recruiting
An open-label, multicenter, Phase I/IIa study assessing the safety and efficacy of EGFR targeted EDVsTM carrying cytotoxic drug PNU-159682 plus concurrent immunomodulatory adjuvant non-targeted EDVs carrying a-galactosyl ceramide in subjects with advanced EGFR-expressing cancers who have failed second-line therapy or where first- and/or second-line therapy is not appropriate (EGFR EDV-D682/GC Trial) (
ENG19
)
EnGeneIC Dream Vector-nanocells-delivered,EGFR-targeting
Colorectal cancer
Kidney cancer
Lung cancer
Mesothelioma
Non-small cell lung cancer
Pancreatic adenocarcinoma
Solid tumour
Triple-negative breast cancer
NSW
2060 - North Sydney - Mater Hospital
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
ACTRN12624001230549
Curative
Phase 2 / Phase 3
Not yet recruiting
An assessment of cancer outcomes post cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal metastases with the use of a personalised aproach to choice of intraperitoneal chemotherapy agent individualised to a patient's specific tumour sensitivity in-vitro.
Irinotecan
Mitomycin
Oxaliplatin
antineoplastic antibiotic
cancer therapy
cytotoxic chemotherapy
platinum-based antineoplastic agent
topoisomerase inhibitor
Colorectal cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2217 - Kogarah - St George Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6027 - Joondalup - Joondalup Health Campus
ACTRN12624001164583
Curative
Not Applicable
Recruiting
Exploring the Utility of Peritoneal Tumour DNA to Detect Clinically Occult Peritoneal Metastasis in Locally Advanced Colon Cancer (
DETECT-PM
) in adults
Colon adenocarcinoma
VIC
3011 - Footscray - Footscray Hospital
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
ACTRN12623001333606
Curative
Phase 2
Not yet recruiting
The Novel use of Labetuzumab as Adjuvant Immunotherapy in Patients with Primary Colon Adenocarcinoma with Intact PELPK Binding Motif in their CEACAM5 gene in a Phase II clinical trial regarding the Development of Metachronous Liver Metastases (i.e., those at ‘high-risk’ of metachronous CRCLMs) (
CCaLM
)
anti-CEACAM5 monoclonal antibody
Colon adenocarcinoma
NSW
2217 - Kogarah - St George Hospital
ACTRN12623000874617
Advanced
Phase 2
Recruiting
Phase II single arm study to explore the efficacy of cetuximab (in combination with irinotecan based treatment) in advanced stage RAS/BRAF wild-type right-sided colorectal cancer with high AREG/EREG expression (
Biomarcer-2
)
anti-EGFR monoclonal antibody
topoisomerase inhibitor
Colorectal cancer
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3011 - Footscray - Footscray Hospital
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit
3844 - Traralgon - Latrobe Regional Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
ACTRN12621001198819
Radonc
Not Applicable
Recruiting
A Phase II Trial to Evaluate Progression-Free Survival in Integrating Local Ablative Therapy with First-Line Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer (
RESOLUTE
)
Radiotherapy
cancer therapy
Colorectal cancer
NSW
2640 - Albury - Border Medical Oncology Research Unit
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
3066 - Epping - Northern Hospital
3128 - Box Hill - Box Hill Hospital - Eastern Health
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
3677 - Wangaratta - Northeast Health Wangaratta
ACTRN12620000757910
Radonc
Not Applicable
Recruiting
Functional imaging-guided radiotherapy dose escalation in rectal adenocarcinoma: a feasibility study (
FIGURE-rectal
)
radiotherapy
Rectal adenocarcinoma
QLD
4575 - Birtinya - Sunshine Coast University Hospital
NCT03906331
Advanced
Approved for marketing
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
RET-selective inhibitor
RET inhibitor
Selpercatinib
cancer therapy
cancer therapy,RET-targeting
Breast cancer
Colon adenocarcinoma
Medullary thyroid cancer
Non-small cell lung cancer
Pancreatic cancer
Papillary thyroid cancer
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4032 - Chermside - The Prince Charles Hospital
WA
6009 - Nedlands - Linear Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT03900442
Advanced
Phase 1
Unknown status
Phase 1 Pharmacodynamic and Pharmacokinetic Study of the Geranylgeranyltransferase I Inhibitor PTX-100 (GGTI-2418) in Patients With Advanced Malignancies (
PTX-100-PD-012017
)
geranylgeranyl transferase inhibitor
Colorectal cancer
Gastric cancer
Multiple myeloma
Pancreatic adenocarcinoma
Peripheral T-cell lymphoma
VIC
3002 - East Melbourne - Epworth Freemasons
ACTRN12625000906459
Advanced
Not Applicable
Active not recruiting
Testing the feasibility, acceptability and impact of an online delivered stress management program for Australian with breast and colorectal cancer: a pilot study
Breast cancer
Colorectal cancer
ACTRN12617001190392
Advanced
Phase 1 / Phase 2
Status unknown
An open label phase IB/II, non-randomised, dose-finding, safety and tolerability study of Panitumumab, Irinotecan, Trifluridine/Tipiracil in RAS wild-type patients with metastatic colorectal cancer (
PIT-Study
)
Tipiracil Hydrochloride
Trifluridine
anti-EGFR monoclonal antibody
antimetabolite
thymidine phosphorylase inhibitor
topoisomerase inhibitor
Colorectal cancer
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5011 - Woodville South - The Queen Elizabeth Hospital
5042 - Bedford Park - Flinders Medical Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (48)
Not yet recruiting (8)
Approved for marketing (1)
Unknown status (1)
Active not recruiting (1)
Status unknown (1)
Recruitment Country and State
VIC (41)
NSW (40)
QLD (29)
WA (21)
SA (20)
NZ (5)
TAS (1)
ACT (1)
Phase
Phase 1 (17)
Phase 1 / Phase 2 (14)
Phase 2 (12)
Phase 2 / Phase 3 (2)
Phase 3 (8)
Trial Type
Advanced (45)
Radonc (10)
Curative (5)
Cancer Therapy Class
PD-1/PD-L1
33%
PD-1
25%
VEGF
22%
EGFR
20%
KRAS
12%
KRAS G12C
10%
PD-L1
8%
MET
8%
WRN
3%
HDAC
3%
VEGFR2
3%
VEGFA
3%
SMO
3%
CTLA4
3%
ERBB2
3%
PI3Kalpha
3%
B7H3
3%
VEGFR1
2%
VEGFR3
2%
prostaglandin DP1 receptor
2%
prostaglandin EP2 receptor
2%
prostaglandin EP4 receptor
2%
CDK4
2%
CDK6
2%
ER
2%
oestrogen axis
2%
Trop2
2%
FR-alpha
2%
DPD
2%
orotate phosphoribosyltransferase
2%
HRAS G12C
2%
NRAS G12C
2%
LGR5
2%
MNK
2%
CDH17
2%
AXL
2%
LAG3
2%
MER
2%
IL-2
2%
CDK7
2%
TIGIT
2%
CCR8
2%
TP53
2%
TP53 Y220C
2%
ALK
2%
MEK
2%
PKC
2%
ROS1
2%
CEACAM5
2%
RET
2%
geranylgeranyl transferase
2%
Facility
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (14)
3000 - Melbourne - Peter MacCallum Cancer Centre (13)
4102 - Woolloongabba - Princess Alexandra Hospital (11)
2050 - Camperdown - Chris O'Brien Lifehouse (11)
5011 - Woodville South - The Queen Elizabeth Hospital (10)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (9)
3168 - Clayton - Monash Medical Centre (7)
5042 - Bedford Park - Flinders Medical Centre (7)
6009 - Nedlands - Linear Clinical Research (6)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (6)
4575 - Birtinya - Sunshine Coast University Hospital (6)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (5)
3004 - Melbourne, Southbank - Alfred Health (5)
2031 - Randwick - Scientia Clinical Research Ltd (5)
2109 - North Ryde - Macquarie University Hospital (5)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (5)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (5)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (5)
6009 - Nedlands - One Clinical Research (5)
3128 - Box Hill - Box Hill Hospital - Eastern Health (4)
6150 - Murdoch - Fiona Stanley Hospital (4)
2170 - Liverpool - Liverpool Hospital (4)
3021 - St Albans - Western Health - Sunshine Hospital (4)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (4)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (4)
3199 - Frankston - Peninsula Health Frankston Hospital (4)
2500 - Wollongong - Wollongong Hospital (3)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (3)
3011 - Footscray - Footscray Hospital (3)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (3)
3066 - Epping - Northern Hospital (3)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (3)
3002 - East Melbourne - Epworth Freemasons (3)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (3)
3065 - Fitzroy - St Vincent's Hospital Melbourne (3)
6009 - Nedlands - Hollywood Private Hospital (2)
2031 - Randwick - Prince of Wales Hospital (2)
2065 - St Leonards - GenesisCare North Shore Private Hospital (2)
4120 - Greenslopes - Greenslopes Private Hospital (2)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (2)
3051 - North Melbourne - Melbourne Theranostic Innovation Centre (2)
4215 - Southport - Tasman Oncology (2)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (2)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (2)
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit (2)
2640 - Albury - Border Medical Oncology Research Unit (2)
2217 - Kogarah - St George Hospital (2)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (1)
2640 - Albury - Albury Wodonga Regional Cancer Centre (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre (1)
3199 - Frankston - PASO Medical (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
7000 - Hobart - ICON Cancer Care Hobart (1)
3630 - Shepparton - Goulburn Valley Health (1)
5112 - Elizabeth Vale - Lyell McEwin Hospital (1)
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre (1)
2500 - Wollongong - Cancer Care Wollongong (1)
2139 - Concord - Concord Repatriation General Hospital (1)
3084 - Heidelberg - Warringal Private Hospital (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
4350 - Toowoomba - Toowoomba Hospital (1)
NA
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit (1)
4217 - Benowa - Pindara Private Hospital (1)
2217 - Kogarah - St George Private Hospital (1)
NZ.3210 - Hamilton - Waikato Hospital (1)
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
2060 - North Sydney - Mater Hospital (1)
6027 - Joondalup - Joondalup Health Campus (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital (1)
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre (1)
2605 - Garran - The Canberra Hospital (1)
3844 - Traralgon - Latrobe Regional Hospital (1)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (1)
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre (1)
3677 - Wangaratta - Northeast Health Wangaratta (1)
4032 - Chermside - The Prince Charles Hospital (1)
Cancer Type
Cancer
Gastrointestinal cancer
Lower gastrointestinal cancer
Solid tumour
Colorectal cancer
Upper gastrointestinal cancer
Thoracic cancer
Lung cancer
Respiratory tract cancer
Non-small cell lung cancer
Pancreatic cancer
Pancreatobiliary cancer
Colorectal adenocarcinoma
Breast cancer
Urogenital cancer
Gastroesophageal cancer
Gynaecological cancer
Gastric cancer
Head and neck cancer
Ovarian cancer
Kidney cancer
Breast adenocarcinoma
Endometrial cancer
Oesophageal cancer
Triple-negative breast cancer
HPV-related cancer
HPV16-positive cancer
Viral-related cancer
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
Bladder cancer
Melanoma
Head and neck squamous cell carcinoma
Hepatobiliary cancer
Clear cell renal cell carcinoma
Cervical cancer
Hepatocellular carcinoma
Male genital cancers
Prostate cancer
Skin cancer
Colon adenocarcinoma
Urothelial carcinoma
Gastric carcinoma
Gastroesophageal junction adenocarcinoma
Rectal adenocarcinoma
Non-squamous non-small-cell lung cancer
Sarcoma
Cutaneous melanoma
Carcinoma
Epithelial Ovarian Cancer
Cutaneous squamous cell carcinoma
Non-melanoma skin cancer
Biomarker-defined solid tumour
MSI-H/dMMR solid tumour
dMMR solid cancer
Mucosal melanoma
Uveal melanoma
HER2-negative breast cancer
HER2-positive breast cancer
Oesophageal adenocarcinoma
Biliary tract cancer
Castrate-resistant prostate cancer
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
Neuroendocrine carcinoma
Prostate adenocarcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Anal cancer
Anal squamous cell carcinoma
Squamous non-small-cell lung cancer
Mesothelioma
Endocrine gland cancer
Thyroid cancer
Lung adenocarcinoma
Microsatellite instability high solid tumour
Mismatch repair deficient colorectal cancer
Dedifferentiated liposarcoma
Fibrosarcoma
Liposarcoma
Soft tissue sarcoma
Solitary fibrous tumour
Undifferentiated pleomorphic sarcoma
RAS-mutant colorectal cancer
Gastrooesophageal adenicarcoma
High-grade serous ovarian cancer
Ovarian adenocarcinoma
Ovarian serous carcinoma
Platinum resistant ovarian cancer
Cholangiocarcinoma
Gastro-entero-pancreatic neuroendocrine tumour
Neuroendocrine tumour
Non-clear cell renal cell carcinoma
Acral lentiginous melanoma
Cutaneous basal cell carcinoma
Endometrial carcinoma
Fallopian tube cancer
Merkel cell carcinoma
Peritoneal cancer
Pleural mesothelioma
Primary peritoneal serous carcinoma
Microsatellite stable colorectal cancer
Non-microsatellite instability-high colorectal cancer
Squamous cell carcinoma
Central nervous system cancer
Glioblastoma
Glioma
High-grade glioma
MET:alteration
MET:fusion
Malignant glioma
Neurological cancer
Differentiated thyroid carcinoma
Medullary thyroid cancer
Papillary thyroid cancer
Haematological malignancy
Lymphoma
Multiple myeloma
Non-Hodgkin's lymphoma
Peripheral T-cell lymphoma
Plasma cell disorder
T-cell lymphoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy